The potential of deferasirox as a novel therapeutic modality in gastric cancer

The potential of deferasirox as a novel therapeutic modality in gastric cancer

Bibliographic Details
Main Authors:	Choi, Jung Hye, Kim, Jung Soon, Won, Young Woong, Uhm, Jieun, Park, Byeong Bae, Lee, Young Yiul
Format:	Online
Language:	English
Published:	BioMed Central 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785730/

Similar Items

Effects of oral iron chelator deferasirox on human malignant lymphoma cells
by: Choi, Jong Gwon, et al.
Published: (2012)

Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent
by: Lee, Ji Won, et al.
Published: (2013)

Hypersensitivity reaction with deferasirox
by: Sharma, Atul, et al.
Published: (2015)

Gastric antral vascular ectasia: the evolution of therapeutic modalities
by: Naidu, Harini, et al.
Published: (2014)

HER2 as a novel therapeutic target for cervical cancer
by: Oh, Doo-Yi, et al.
Published: (2015)

Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
by: Kim, Dae Sik, et al.
Published: (2016)

Deferasirox: appraisal of safety and efficacy in long-term therapy
by: Chaudhary, Preeti, et al.
Published: (2013)

Deferasirox Reduces Oxidative Stress in Patients With Transfusion Dependency
by: Saigo, Katsuyasu, et al.
Published: (2013)

Gingival Pigmentation Reduction: A Novel Therapeutic Modality
by: Mahesh, H V, et al.
Published: (2012)

Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer
by: Jung, Hun Soon, et al.
Published: (2015)

Acidic Water Bathing Could Be a Safe and Effective Therapeutic Modality for Severe and Refractory Atopic Dermatitis
by: Lee, Noo Ri, et al.
Published: (2016)

Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target
by: HUR, HOON, et al.
Published: (2012)

Therapeutic Value of Combined Therapy with Deferasirox and Silymarin on Iron Overload in Children with Beta Thalassemia
by: Hagag, Adel A., et al.
Published: (2013)

Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro
by: Hwang, Mi-Hye, et al.
Published: (2015)

Treatment modalities for patients with gambling disorder
by: Sam-Wook Choi, et al.
Published: (2017-04-01)

Recent advance in brown adipose physiology and its therapeutic potential
by: Lee, Yun-Hee, et al.
Published: (2014)

The Factors Associated with Contact Burns from Therapeutic Modalities
by: Mun, Jeong-Hyeon, et al.
Published: (2012)

MCT4 as a potential therapeutic target for metastatic gastric cancer with peritoneal carcinomatosis
by: Lee, Ji Yun, et al.
Published: (2016)

Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis
by: Maker, G., et al.
Published: (2013)

Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia
by: Pennell, D.J., et al.
Published: (2010)

Iron Chelation Therapy with Deferasirox in the Management of Iron Overload in Primary Myelofibrosis
by: Elli, Elena Maria, et al.
Published: (2014)

Deferasirox in Indian children with thalassemia major: 3 years experience
by: Dhamija, Mayank, et al.
Published: (2013)

Perforated duodenal ulcer: A rare complication of deferasirox in children
by: Yadav, Sunil Kumar, et al.
Published: (2013)

Evaluation of conventional renal function tests in patients with ?-thalassemia major using deferasirox
by: Nor Fathihah binti Mamat
Published: (2013)

ANALYSIS OF DEFERASIROX AND DEFERIPRON USE IN CHILDREN WITH PEDIATRIC -THALASSEMIA MAJOR
by: Evy Sari Sutrisnaningsih, et al.
Published: (2017-08-01)

Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
by: Yamamoto, Naoki, et al.
Published: (2016)

Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
by: Saeki, Issei, et al.
Published: (2016)

Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
by: Ricchi, Paolo, et al.
Published: (2015)

Anti-leukemic properties of deferasirox via apoptosis in murine leukemia cell lines
by: Jeon, Sol-Rim, et al.
Published: (2015)

Novel diagnostic and therapeutic modalities using endoscopic ultrasound in pancreatic disease
by: Anjuli Kristin Luthra, et al.
Published: (2017-03-01)

Therapeutic Strategies in HCC: Radiation Modalities
by: Gallicchio, R., et al.
Published: (2016)

Therapeutic outcomes of mandibular advancement devices as an initial treatment modality for obstructive sleep apnea
by: Park, Pona, et al.
Published: (2016)

A Case of Metastatic Gastric Neuroendocrine Tumor: Therapeutic Considerations
by: Kim, Shin Young, et al.
Published: (2014)

Pain modality and spinal glia expression by streptozotocin induced diabetic peripheral neuropathy in rats
by: Kim, Sok Ho, et al.
Published: (2012)

Potential Role of Thymosin Beta 4 in Liver Fibrosis
by: Kim, Jieun, et al.
Published: (2015)

Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer
by: Hwang, Jun-Eul, et al.
Published: (2013)

Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
by: Harima, Hirofumi, et al.
Published: (2016)

NKX6.3 controls gastric differentiation and tumorigenesis
by: Yoon, Jung Hwan, et al.
Published: (2015)

Two Atypical Cases of Nodular Gastritis: A Poorly Differentiated Gastric Adenocarcinoma and a Pseudo-Low Grade Gastric MALT Lymphoma
by: Choi, Hye Jin, et al.
Published: (2010)

A Case of Primary Adrenal Gland Lymphoma
by: Yoon, Jae Hee, et al.
Published: (2003)